An analysis of FDA-approved drugs for metabolic diseases. Issue 6 (June 2015) - Kinch, Michael S.
Highlights Growth in NMEs recently emphasizes genetic disorders. Genetic and nongenetic disorders utilize very different targets and approaches. Whereas pharma dominates diabetes, biotech is more prominent in genetic diseases.